FDA / 2024–2026
FDA briefing and compounding safety concerns for ipamorelin
FDA briefing and compounding safety concerns for ipamorelin — U.S. FDA (2024–2026), cited in PeptideAgent's Ipamorelin evidence record.
Open original sourceSOURCE METADATA
What this record represents.
- Publisher
- U.S. FDA
- Evidence type
- FDA
- Publication year
- 2024–2026
- Source ID
- fda-ipamorelin-risk
WHERE THIS IS CITED